LXE408

Small molecule

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Visceral Leishmaniasis
NCT05593666 · Drugs for Neglected Diseases
2022-12-27 – 2025-12-22 · Primary Visceral Leishmaniasis
What this study did
NCT05957978 · Drugs for Neglected Diseases
2024-03-29 – 2025-11-13 · Primary Visceral Leishmaniasis
What this study did
Other / comorbidity
NCT06632600 · Novartis Pharmaceuticals
2025-04-28 – 2031-01-21 · Chagas Disease
What this study did
Phase 1 (1)
Visceral Leishmaniasis
NCT07809919 · Novartis Pharmaceuticals
2018-12-21 – 2021-09-27 · Visceral Leishmaniasis, Chagas Disease
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow LXE408 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Phase 2Chagas DiseaseRecruiting
Est. primary completion 2027-07-22 · NCT06632600 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Phase 2Localized Cutaneous LeishmaniasisNot yet recruiting
Est. primary completion 2028-04-05 · NCT06997159 · CT.gov ↗
What to watch

See the full readout calendar ↗